You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDigoxin
Accession NumberDB00390  (APRD00098)
TypeSmall Molecule
GroupsApproved
DescriptionA cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone digoxigenin. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
Structure
Thumb
Synonyms
12beta-Hydroxydigitoxin
12β-hydroxydigitoxin
4-[(3S,5R,8R,9S,10S,12R,13S,14S)-3-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-5-[(2S,4S,5R,6R)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one
Digazolan
Digossina
Digoxin
Digoxina
Digoxine
Digoxinum
Lanadicor
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Digoxintablet.25 mg/1oralAvera Mc Kennan Hospital2015-03-09Not applicableUs
Digoxintablet.125 mg/1oralAvera Mc Kennan Hospital2015-03-02Not applicableUs
Digoxinsolution.05 mg/mLoralRoxane Laboratories, Inc2004-08-26Not applicableUs
Digoxinsolution.05 mg/mLoralAtlantic Biologicals Corps2004-08-26Not applicableUs
Digoxintablet.25 mg/1oralPar Pharmaceutical Inc.2014-01-14Not applicableUs
Digoxintablet.125 mg/1oralCardinal Health2014-01-14Not applicableUs
Digoxintablet.125 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Digoxintablet.125 mg/1oralPar Pharmaceutical Inc.2014-01-14Not applicableUs
Digoxinsolution.05 mg/mLoralPrecision Dose Inc.2012-05-04Not applicableUs
Digoxintablet.125 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-01-14Not applicableUs
Digoxin Injection C.S.D.liquid0.25 mgintramuscular; intravenousSandoz Canada Incorporated1994-12-31Not applicableCanada
Lanoxininjection, solution100 ug/mLintramuscular; intravenousCovis Pharmaceuticals, Inc.2013-01-14Not applicableUs
Lanoxintablet250 ug/1oralPd Rx Pharmaceuticals, Inc.1984-07-02Not applicableUs
Lanoxintablet0.0625 mgoralPharmascience Inc2001-06-22Not applicableCanada
Lanoxininjection, solution250 ug/mLintramuscular; intravenousCardinal Health1985-10-01Not applicableUs
Lanoxintablet.25 mg/1oralConcordia Pharmaceuticals Inc.2012-09-30Not applicableUs
Lanoxintablet.1875 mg/1oralCovis Pharmaceuticals, Inc.2012-09-30Not applicableUs
Lanoxintablet125 ug/1oralREMEDYREPACK INC.2013-03-042016-03-31Us
Lanoxintablet.0625 mg/1oralConcordia Pharmaceuticals Inc.2012-09-30Not applicableUs
Lanoxintablet250 ug/1oralCardinal Health1997-09-30Not applicableUs
Lanoxintablet0.125 mgoralPharmascience Inc2001-03-16Not applicableCanada
Lanoxintablet125 ug/1oralRx Pak Division Of Mc Kesson Corporation1984-09-14Not applicableUs
Lanoxintablet.25 mg/1oralCovis Pharmaceuticals, Inc.2012-09-30Not applicableUs
Lanoxintablet125 ug/1oralCardinal Health1997-09-30Not applicableUs
Lanoxintablet.0625 mg/1oralCovis Pharmaceuticals, Inc.2012-09-30Not applicableUs
Lanoxintablet.125 mg/1oralConcordia Pharmaceuticals Inc.2012-09-30Not applicableUs
Lanoxintablet0.25 mgoralPharmascience Inc2001-03-16Not applicableCanada
Lanoxintablet.125 mg/1oralCardinal Health2012-09-30Not applicableUs
Lanoxininjection, solution250 ug/mLintramuscular; intravenousCovis Pharmaceuticals, Inc.2013-02-15Not applicableUs
Lanoxintablet125 ug/1oralCardinal Health1997-09-30Not applicableUs
Lanoxintablet.1875 mg/1oralConcordia Pharmaceuticals Inc.2012-09-30Not applicableUs
Lanoxintablet.125 mg/1oralCovis Pharmaceuticals, Inc.2012-09-30Not applicableUs
Lanoxintablet.25 mg/1oralCardinal Health2012-09-30Not applicableUs
Lanoxin Elx 0.05mg/ml Pediatricliquid.05 mgoralGlaxo Wellcome Inc.1956-12-312003-07-31Canada
Lanoxin Inj 0.05mg/ml Pediatricliquid.05 mgintramuscular; intravenousGlaxo Wellcome Inc.1963-12-312001-08-02Canada
Lanoxin Inj 0.25mg/mlliquid.25 mgintramuscular; intravenousGlaxo Wellcome Inc.1955-12-312001-08-02Canada
Lanoxin Tab 0.0625mgtablet.0625 mgoralGlaxo Wellcome Inc.1987-12-312001-08-02Canada
Lanoxin Tab 0.125mgtablet.125 mgoralGlaxo Wellcome Inc.1971-12-312001-08-02Canada
Lanoxin Tab 0.25mgtablet.25 mgoralGlaxo Wellcome Inc.1936-12-312001-08-02Canada
Novo-digoxin Tab 0.25mgtablet.25 mgoralNovopharm Limited1966-12-312004-11-05Canada
Pediatric Digoxin Injection C.S.D.liquid0.05 mgintramuscular; intravenousSandoz Canada Incorporated1994-12-31Not applicableCanada
PMS-digoxintablet0.125 mgoralPharmascience Inc2006-06-21Not applicableCanada
PMS-digoxintablet0.25 mgoralPharmascience Inc2006-06-21Not applicableCanada
PMS-digoxintablet0.0625 mgoralPharmascience Inc2006-06-21Not applicableCanada
Toloxintablet0.250 mgoralPendopharm Division Of De Pharmascience Inc2009-12-23Not applicableCanada
Toloxintablet0.0625 mgoralPendopharm Division Of De Pharmascience Inc2009-12-23Not applicableCanada
Toloxinsolution0.05 mgoralPendopharm Division Of De Pharmascience Inc2001-06-01Not applicableCanada
Toloxintablet0.125 mgoralPendopharm Division Of De Pharmascience Inc2009-12-23Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-digoxintablet0.125 mgoralApotex Inc2006-06-22Not applicableCanada
Apo-digoxintablet0.0625 mgoralApotex Inc2006-06-22Not applicableCanada
Apo-digoxintablet0.25 mgoralApotex Inc2006-06-22Not applicableCanada
Digitektablet.25 mg/1oralMylan Institutional Inc.2015-06-18Not applicableUs
Digitektablet.125 mg/1oralMylan Institutional Inc.2015-06-18Not applicableUs
Digitektablet.125 mg/1oralMylan Pharmaceuticals Inc.2014-11-17Not applicableUs
Digitektablet.25 mg/1oralMylan Pharmaceuticals Inc.2014-11-17Not applicableUs
Digoxtablet125 ug/1oralTYA Pharmaceuticals2002-07-26Not applicableUs
Digoxtablet250 ug/1oralUnit Dose Services2002-07-26Not applicableUs
Digoxtablet250 ug/1oralPd Rx Pharmaceuticals, Inc.2002-07-26Not applicableUs
Digoxtablet250 ug/1oralREMEDYREPACK INC.2015-12-30Not applicableUs
Digoxtablet250 ug/1oralCarilion Materials Management2002-07-26Not applicableUs
Digoxtablet125 ug/1oralLannett Company, Inc.2002-07-26Not applicableUs
Digoxtablet250 ug/1oralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs
Digoxtablet250 ug/1oralREMEDYREPACK INC.2013-03-052016-04-05Us
Digoxtablet250 ug/1oralLannett Company, Inc.2002-07-26Not applicableUs
Digoxtablet125 ug/1oralLake Erie Medical DBA Quality Care Products LLC2002-07-26Not applicableUs
Digoxtablet125 ug/1oralMc Kesson Contract Packaging2012-09-28Not applicableUs
Digoxtablet250 ug/1oralUnit Dose Services2002-07-26Not applicableUs
Digoxtablet125 ug/1oralCarilion Materials Management2002-07-26Not applicableUs
Digoxtablet.125 mg/1oralSt Marys Medical Park Pharmacy2013-05-02Not applicableUs
Digoxtablet250 ug/1oralAidarex Pharmaceuticals LLC2002-07-26Not applicableUs
Digoxintablet.125 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-30Not applicableUs
Digoxintablet250 ug/1oralPhysicians Total Care, Inc.2000-08-21Not applicableUs
Digoxintablet125 ug/1oralWest Ward Pharmaceuticals Corp2007-10-30Not applicableUs
Digoxintablet125 ug/1oralDEPT HEALTH CENTRAL PHARMACY2008-05-01Not applicableUs
Digoxininjection.25 mg/mLintramuscular; intravenousWest Ward Pharmaceuticals Corp.1975-10-24Not applicableUs
Digoxininjection.25 mg/mLintramuscular; intravenousCardinal Health2011-06-28Not applicableUs
Digoxintablet.125 mg/301oralNorthwind Pharmaceuticals2014-05-16Not applicableUs
Digoxintablet250 ug/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Digoxintablet125 ug/1oralREMEDYREPACK INC.2014-10-08Not applicableUs
Digoxintablet125 ug/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-26Not applicableUs
Digoxintablet125 ug/1oralPhysicians Total Care, Inc.1992-09-22Not applicableUs
Digoxintablet125 ug/1oralAmerican Health Packaging2014-09-23Not applicableUs
Digoxintablet125 ug/1oralJerome Stevens Pharmaceuticals, Inc.2002-07-26Not applicableUs
Digoxintablet250 ug/1oralWest Ward Pharmaceuticals Corp2007-10-30Not applicableUs
Digoxintablet125 ug/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Digoxintablet125 ug/1oralSun Pharmaceutical Industries, Inc.2015-02-17Not applicableUs
Digoxininjection, solution250 ug/mLintramuscular; intravenous; parenteralSandoz Inc2003-08-21Not applicableUs
Digoxintablet125 ug/1oralCardinal Health2009-12-01Not applicableUs
Digoxintablet125 ug/1oralMc Kesson Contract Packaging2011-10-11Not applicableUs
Digoxintablet125 ug/1oralREMEDYREPACK INC.2014-01-302016-04-05Us
Digoxintablet125 ug/1oralA S Medication Solutions Llc2007-10-30Not applicableUs
Digoxintablet125 ug/1oralbryant ranch prepack2007-10-30Not applicableUs
Digoxintablet250 ug/1oralJerome Stevens Pharmaceuticals, Inc.2002-07-26Not applicableUs
Digoxintablet250 ug/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-07-26Not applicableUs
Digoxintablet125 ug/1oralCardinal Health2011-07-01Not applicableUs
Digoxintablet250 ug/1oralAmerican Health Packaging2014-09-22Not applicableUs
Digoxintablet250 ug/1oralSun Pharmaceutical Industries, Inc.2015-02-17Not applicableUs
Digoxintablet125 ug/1oralImpax Generics2009-07-20Not applicableUs
Digoxintablet125 ug/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Digoxintablet125 ug/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Digoxintablet125 ug/1oralCardinal Health2009-06-10Not applicableUs
Digoxininjection250 ug/mLintramuscular; intravenousGeneral Injecatables & Vaccines, Inc2010-07-01Not applicableUs
Digoxintablet250 ug/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-30Not applicableUs
Digoxintablet250 ug/1oralA S Medication Solutions Llc2007-10-30Not applicableUs
Digoxintablet250 ug/1oralbryant ranch prepack2007-10-30Not applicableUs
Digoxintablet250 ug/1oralCardinal Health2011-07-01Not applicableUs
Digoxintablet.25 mg/301oralNorthwind Pharmaceuticals2014-05-16Not applicableUs
Digoxininjection.25 mg/mLintramuscular; intravenousWest Ward Pharmaceuticals Corp.1975-10-24Not applicableUs
Digoxintablet250 ug/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Digoxintablet.125 mg/1oralREMEDYREPACK INC.2011-07-20Not applicableUs
Digoxintablet250 ug/1oralImpax Generics2009-07-20Not applicableUs
Digoxintablet250 ug/1oralMajor Pharmaceuticals2009-06-10Not applicableUs
Digoxintablet125 ug/1oralPd Rx Pharmaceuticals, Inc.2002-07-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AgoxinAristopharma
CardiacinCenter
CardiogoxinMedipharma
CardioxinOboi
CardoxinNot Available
CeloxinCelon
CentoxinOpsonin
Digacinmibe
Digocard-GKlonal
DigoxinaGlaxoSmithKline
EudigoxTeofarma
LanacordinKern
LanacristNot Available
LanicorRoche
LanoxicapsNot Available
LenoxinGlaxoSmithKline
Brand mixturesNot Available
SaltsNot Available
Categories
UNII73K4184T59
CAS number20830-75-5
WeightAverage: 780.9385
Monoisotopic: 780.429606756
Chemical FormulaC41H64O14
InChI KeyInChIKey=LTMHDMANZUZIPE-PUGKRICDSA-N
InChI
InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1
IUPAC Name
4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl]-2,5-dihydrofuran-2-one
SMILES
[H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[[email protected]](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[[email protected]]1C[[email protected]](O)[[email protected]](O[[email protected]]2C[[email protected]](O)[[email protected]](O[[email protected]]3C[[email protected]](O)[[email protected]](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid lactones
Direct ParentCardenolide glycosides and derivatives
Alternative Parents
Substituents
  • Cardanolide-glycoside
  • Steroidal glycoside
  • Oligosaccharide
  • Hydroxysteroid
  • 12-hydroxysteroid
  • Oxane
  • Saccharide
  • 2-furanone
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Tertiary alcohol
  • Dihydrofuran
  • Cyclic alcohol
  • Secondary alcohol
  • Lactone
  • Carboxylic acid ester
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment and management of congestive cardiac insufficiency, arrhythmias and heart failure.
PharmacodynamicsDigoxin, a cardiac glycoside similar to digitoxin, is used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation.
Mechanism of actionDigoxin inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium. The sodium calcium exchanger (NCX)in turn tries to extrude the sodium and in so doing, pumps in more calcium. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Digoxin also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
Related Articles
AbsorptionAbsorption of digoxin from the elixir pediatric formulation has been demonstrated to be 70% to 85% complete (90% to 100% from the capsules, and 60% to 80% for tablets).
Volume of distributionNot Available
Protein binding25%
Metabolism

Hepatic (but not dependent upon the cytochrome P-450 system). The end metabolites, which include 3 b-digoxigenin, 3-keto-digoxigenin, and their glucuronide and sulfate conjugates, are polar in nature and are postulated to be formed via hydrolysis, oxidation, and conjugation.

SubstrateEnzymesProduct
Digoxin
Not Available
3 b-digoxigeninDetails
Digoxin
Not Available
3-keto-digoxigeninDetails
Route of eliminationFollowing intravenous administration to healthy volunteers, 50% to 70% of a digoxin dose is excreted unchanged in the urine.
Half life3.5 to 5 days
ClearanceNot Available
ToxicityToxicity includes ventricular tachycardia or ventricular fibrillation, or progressive bradyarrhythmias, or heart block. LD50 = 7.8 mg/kg (orally in mice).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.941
Blood Brain Barrier-0.7241
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8586
P-glycoprotein inhibitor INon-inhibitor0.5325
P-glycoprotein inhibitor IINon-inhibitor0.6209
Renal organic cation transporterNon-inhibitor0.8621
CYP450 2C9 substrateNon-substrate0.855
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7366
CYP450 1A2 substrateNon-inhibitor0.9261
CYP450 2C9 inhibitorNon-inhibitor0.9196
CYP450 2D6 inhibitorNon-inhibitor0.9359
CYP450 2C19 inhibitorNon-inhibitor0.9385
CYP450 3A4 inhibitorNon-inhibitor0.9279
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9279
Ames testNon AMES toxic0.9233
CarcinogenicityNon-carcinogens0.9668
BiodegradationNot ready biodegradable0.9555
Rat acute toxicity4.4721 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9818
hERG inhibition (predictor II)Inhibitor0.8051
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline llc
  • Roxane laboratories inc
  • Abraxis pharmaceutical products
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Sandoz canada inc
  • Wyeth ayerst laboratories
  • Actavis totowa llc
  • Caraco pharmaceutical laboratories ltd
  • Impax laboratories inc
  • Jerome stevens pharmaceuticals inc
  • West ward pharmaceutical corp
  • Smithkline beecham corp dba glaxosmithkline
Packagers
Dosage forms
FormRouteStrength
Tabletoral.125 mg/1
Tabletoral.25 mg/1
Injectionintramuscular; intravenous.25 mg/mL
Injectionintramuscular; intravenous250 ug/mL
Injection, solutionintramuscular; intravenous; parenteral250 ug/mL
Solutionoral.05 mg/mL
Tabletoral.125 mg/301
Tabletoral.25 mg/301
Tabletoral125 ug/1
Tabletoral250 ug/1
Liquidintramuscular; intravenous0.25 mg
Injection, solutionintramuscular; intravenous100 ug/mL
Injection, solutionintramuscular; intravenous250 ug/mL
Tabletoral.0625 mg/1
Tabletoral.1875 mg/1
Tabletoral0.0625 mg
Tabletoral0.125 mg
Tabletoral0.25 mg
Liquidoral.05 mg
Liquidintramuscular; intravenous.05 mg
Liquidintramuscular; intravenous.25 mg
Tabletoral.0625 mg
Tabletoral.125 mg
Tabletoral.25 mg
Liquidintramuscular; intravenous0.05 mg
Solutionoral0.05 mg
Tabletoral0.250 mg
Prices
Unit descriptionCostUnit
Digibind 38 mg vial727.91USD vial
Digifab 40 mg vial615.6USD vial
Digoxin powder450.28USD g
Digoxin 0.05 mg/ml Solution 60ml Bottle36.99USD bottle
Lanoxin ped 0.1 mg/ml ampul6.91USD ml
Digoxin Pediatric 0.05 mg/ml6.79USD ml
Digoxin 0.25 mg/ml2.91USD ml
Lanoxin 0.25 mg/ml ampul1.44USD ml
Lanoxin 0.125 mg tablet0.73USD tablet
Lanoxin 0.25 mg tablet0.66USD tablet
Digoxin 0.125 mg tablet0.64USD tablet
Digoxin 0.25 mg tablet0.62USD tablet
Digoxin 0.25 mg/ml ampul0.61USD ml
Lanoxin Pediatric 0.05 mg/ml Elixir0.41USD ml
Lanoxicaps 0.1 mg capsule0.4USD capsule
Lanoxin 125 mcg tablet0.3USD tablet
Lanoxin 250 mcg tablet0.3USD tablet
Digitek 125 mcg tablet0.28USD tablet
Digitek 250 mcg tablet0.28USD tablet
Lanoxicaps 0.05 mg capsule0.28USD capsule
Toloxin 0.0625 mg Tablet0.27USD tablet
Toloxin 0.125 mg Tablet0.27USD tablet
Toloxin 0.25 mg Tablet0.27USD tablet
Digoxin 125 mcg tablet0.22USD tablet
Digoxin 250 mcg tablet0.22USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point217-221Stoll, A .and Kreis, W.; US.Patent 2,776,963; January 8,1957;assigned to Sandoz, AG, Switzerland.
water solubility64.8 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.26SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.127 mg/mLALOGPS
logP1.04ALOGPS
logP2.37ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)7.15ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area203.06 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity193.23 m3·mol-1ChemAxon
Polarizability84.8 Å3ChemAxon
Number of Rings8ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Wolfgang Voigtlander, Fritz Kaiser, Wolfgang Schaumann, Kurt Stach, “Preparation of C22-alkyl derivative of digoxin.” U.S. Patent US3981862, issued October, 1972.

US3981862
General References
  1. Thompson DF, Carter JR: Drug-induced gynecomastia. Pharmacotherapy. 1993 Jan-Feb;13(1):37-45. [PubMed:8094898 ]
  2. Doering W, Konig E, Sturm W: [Digitalis intoxication: specifity and significance of cardiac and extracardiac symptoms. part I: Patients with digitalis-induced arrhythmias (author's transl)]. Z Kardiol. 1977 Mar;66(3):121-8. [PubMed:857452 ]
  3. Kaplanski J, Weinhouse E, Topaz M, Genchik G: Verapamil and digoxin: interactions in the rat. Res Commun Chem Pathol Pharmacol. 1983 Dec;42(3):377-88. [PubMed:6665298 ]
  4. Flanagan RJ, Jones AL: Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33. [PubMed:15554746 ]
External Links
ATC CodesC01AA05
AHFS Codes
  • 24:04.08
  • 80:04.00
PDB EntriesNot Available
FDA labelDownload (563 KB)
MSDSDownload (74.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Digoxin can be increased when it is combined with 1,10-Phenanthroline.
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideDigoxin may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.
2-MethoxyestradiolDigoxin may decrease the cardiotoxic activities of 2-Methoxyestradiol.
3-MethoxybenzamideDigoxin may decrease the cardiotoxic activities of 3-Methoxybenzamide.
3,4-DichloroisocoumarinThe serum concentration of Digoxin can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-Dihydroxybenzoic AcidDigoxin may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Digoxin can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
5,10-Dideazatetrahydrofolic AcidDigoxin may decrease the cardiotoxic activities of 5,10-Dideazatetrahydrofolic Acid.
7-HydroxystaurosporineDigoxin may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.
8-azaguanineDigoxin may decrease the cardiotoxic activities of 8-azaguanine.
9-(2-phosphonylmethoxyethyl)-2,6-diaminopurineDigoxin may decrease the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.
AbirateroneDigoxin may decrease the cardiotoxic activities of Abiraterone.
ABT-263Digoxin may decrease the cardiotoxic activities of ABT-263.
AcarboseThe serum concentration of Digoxin can be decreased when it is combined with Acarbose.
AcebutololAcebutolol may increase the bradycardic activities of Digoxin.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Digoxin.
AceclofenacThe serum concentration of Digoxin can be increased when it is combined with Aceclofenac.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Digoxin.
AcetaminophenThe serum concentration of Digoxin can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidThe serum concentration of Digoxin can be increased when it is combined with Acetylsalicylic acid.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Digoxin.
AdapaleneThe serum concentration of Digoxin can be increased when it is combined with Adapalene.
AdenosineThe risk or severity of adverse effects can be increased when Digoxin is combined with Adenosine.
AfatinibDigoxin may decrease the cardiotoxic activities of Afatinib.
AfatinibThe serum concentration of Digoxin can be increased when it is combined with Afatinib.
AfimoxifeneDigoxin may decrease the cardiotoxic activities of Afimoxifene.
AfliberceptDigoxin may decrease the cardiotoxic activities of Aflibercept.
AlatrofloxacinDigoxin may decrease the cardiotoxic activities of Alatrofloxacin.
AlbendazoleDigoxin may decrease the cardiotoxic activities of Albendazole.
AlbendazoleThe serum concentration of Digoxin can be increased when it is combined with Albendazole.
AldesleukinDigoxin may decrease the cardiotoxic activities of Aldesleukin.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Digoxin.
AlectinibThe serum concentration of Digoxin can be increased when it is combined with Alectinib.
AlemtuzumabDigoxin may decrease the cardiotoxic activities of Alemtuzumab.
AlfentanilThe serum concentration of Digoxin can be increased when it is combined with Alfentanil.
AlitretinoinDigoxin may decrease the cardiotoxic activities of Alitretinoin.
AlogliptinThe serum concentration of Digoxin can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Digoxin can be increased when it is combined with Alpha-1-proteinase inhibitor.
Alpha-DifluoromethylornithineDigoxin may decrease the cardiotoxic activities of Alpha-Difluoromethylornithine.
AlprenololAlprenolol may increase the bradycardic activities of Digoxin.
AltretamineDigoxin may decrease the cardiotoxic activities of Altretamine.
AmantadineThe serum concentration of Digoxin can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Digoxin.
AmikacinThe serum concentration of Digoxin can be decreased when it is combined with Amikacin.
AmilorideThe therapeutic efficacy of Digoxin can be decreased when used in combination with Amiloride.
AminoglutethimideDigoxin may decrease the cardiotoxic activities of Aminoglutethimide.
Aminohippuric acidThe serum concentration of Digoxin can be increased when it is combined with Aminohippuric acid.
Aminolevulinic acidDigoxin may decrease the cardiotoxic activities of Aminolevulinic acid.
AmiodaroneThe serum concentration of Digoxin can be decreased when it is combined with Amiodarone.
AmiodaroneDigoxin may increase the bradycardic activities of Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Digoxin.
AmitriptylineThe serum concentration of Digoxin can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Digoxin can be increased when it is combined with Amlodipine.
AmodiaquineThe serum concentration of Digoxin can be increased when it is combined with Amodiaquine.
AmonafideDigoxin may decrease the cardiotoxic activities of Amonafide.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin.
AmprenavirThe serum concentration of Digoxin can be increased when it is combined with Amprenavir.
AmrubicinDigoxin may decrease the cardiotoxic activities of Amrubicin.
AmsacrineDigoxin may decrease the cardiotoxic activities of Amsacrine.
AmsacrineThe serum concentration of Digoxin can be increased when it is combined with Amsacrine.
AnagrelideDigoxin may decrease the cardiotoxic activities of Anagrelide.
AnastrozoleDigoxin may decrease the cardiotoxic activities of Anastrozole.
annamycinDigoxin may decrease the cardiotoxic activities of annamycin.
AntipyrineThe serum concentration of Digoxin can be increased when it is combined with Antipyrine.
Antithrombin III humanThe serum concentration of Digoxin can be increased when it is combined with Antithrombin III human.
AP 12009Digoxin may decrease the cardiotoxic activities of AP 12009.
AP24534Digoxin may decrease the cardiotoxic activities of AP24534.
ApixabanThe serum concentration of Digoxin can be increased when it is combined with Apixaban.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Digoxin.
ApremilastThe serum concentration of Digoxin can be increased when it is combined with Apremilast.
AprepitantThe serum concentration of Digoxin can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Digoxin can be increased when it is combined with Aprotinin.
ArgatrobanThe serum concentration of Digoxin can be increased when it is combined with Argatroban.
ArotinololArotinolol may increase the bradycardic activities of Digoxin.
Arsenic trioxideDigoxin may decrease the cardiotoxic activities of Arsenic trioxide.
ASA404Digoxin may decrease the cardiotoxic activities of ASA404.
AsparaginaseDigoxin may decrease the cardiotoxic activities of Asparaginase.
AstemizoleThe serum concentration of Digoxin can be increased when it is combined with Astemizole.
AsunaprevirThe serum concentration of Digoxin can be increased when it is combined with Asunaprevir.
AT-101Digoxin may decrease the cardiotoxic activities of AT-101.
AtazanavirThe serum concentration of Digoxin can be increased when it is combined with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Digoxin.
AtenololAtenolol may increase the bradycardic activities of Digoxin.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Digoxin.
AtomoxetineThe metabolism of Digoxin can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Digoxin can be increased when it is combined with Atorvastatin.
AxitinibDigoxin may decrease the cardiotoxic activities of Axitinib.
AzacitidineDigoxin may decrease the cardiotoxic activities of Azacitidine.
AzapropazoneThe serum concentration of Digoxin can be increased when it is combined with Azapropazone.
AzathioprineDigoxin may decrease the cardiotoxic activities of Azathioprine.
AZD2171Digoxin may decrease the cardiotoxic activities of AZD2171.
Azelaic AcidDigoxin may decrease the cardiotoxic activities of Azelaic Acid.
AzelastineThe serum concentration of Digoxin can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Digoxin can be increased when it is combined with Azithromycin.
BalsalazideThe serum concentration of Digoxin can be increased when it is combined with Balsalazide.
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Digoxin.
BatimastatThe serum concentration of Digoxin can be increased when it is combined with Batimastat.
BatimastatDigoxin may decrease the cardiotoxic activities of Batimastat.
BefunololBefunolol may increase the bradycardic activities of Digoxin.
BelinostatDigoxin may decrease the cardiotoxic activities of Belinostat.
BenazeprilThe serum concentration of Digoxin can be increased when it is combined with Benazepril.
BendamustineDigoxin may decrease the cardiotoxic activities of Bendamustine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Digoxin.
BendroflumethiazideDigoxin may increase the bradycardic activities of Bendroflumethiazide.
BenoxaprofenThe serum concentration of Digoxin can be increased when it is combined with Benoxaprofen.
BenzamidineThe serum concentration of Digoxin can be increased when it is combined with Benzamidine.
BenzocaineThe serum concentration of Digoxin can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Digoxin can be increased when it is combined with Bepridil.
BeractantDigoxin may increase the bradycardic activities of Beractant.
BesifloxacinDigoxin may decrease the cardiotoxic activities of Besifloxacin.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Digoxin.
BetaxololBetaxolol may increase the bradycardic activities of Digoxin.
BevacizumabDigoxin may decrease the cardiotoxic activities of Bevacizumab.
BevantololBevantolol may increase the bradycardic activities of Digoxin.
BexaroteneDigoxin may decrease the cardiotoxic activities of Bexarotene.
BexaroteneThe serum concentration of Digoxin can be decreased when it is combined with Bexarotene.
BicalutamideDigoxin may decrease the cardiotoxic activities of Bicalutamide.
BiperidenThe serum concentration of Digoxin can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the bradycardic activities of Digoxin.
BivalirudinThe serum concentration of Digoxin can be increased when it is combined with Bivalirudin.
BleomycinDigoxin may decrease the cardiotoxic activities of Bleomycin.
BlinatumomabDigoxin may decrease the cardiotoxic activities of Blinatumomab.
BoceprevirThe serum concentration of Digoxin can be increased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Digoxin.
BopindololBopindolol may increase the bradycardic activities of Digoxin.
BortezomibDigoxin may decrease the cardiotoxic activities of Bortezomib.
BortezomibThe metabolism of Digoxin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Digoxin can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Digoxin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Digoxin.
BretyliumBretylium may increase the bradycardic activities of Digoxin.
BrimonidineBrimonidine may increase the bradycardic activities of Digoxin.
BromfenacThe serum concentration of Digoxin can be increased when it is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Digoxin.
BromocriptineThe serum concentration of Digoxin can be increased when it is combined with Bromocriptine.
BSI-201Digoxin may decrease the cardiotoxic activities of BSI-201.
BufuralolBufuralol may increase the bradycardic activities of Digoxin.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Digoxin.
BupranololBupranolol may increase the bradycardic activities of Digoxin.
BuprenorphineThe serum concentration of Digoxin can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Digoxin can be increased when it is combined with Buspirone.
BusulfanDigoxin may decrease the cardiotoxic activities of Busulfan.
CabazitaxelDigoxin may decrease the cardiotoxic activities of Cabazitaxel.
CabazitaxelThe serum concentration of Digoxin can be increased when it is combined with Cabazitaxel.
CabergolineDigoxin may decrease the cardiotoxic activities of Cabergoline.
CabozantinibDigoxin may decrease the cardiotoxic activities of Cabozantinib.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Digoxin.
CaffeineThe serum concentration of Digoxin can be increased when it is combined with Caffeine.
CalcipotriolDigoxin may decrease the cardiotoxic activities of Calcipotriol.
CalfactantDigoxin may increase the bradycardic activities of Calfactant.
CamptothecinDigoxin may decrease the cardiotoxic activities of Camptothecin.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Digoxin.
CanagliflozinThe serum concentration of Digoxin can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Digoxin can be increased when it is combined with Candesartan.
CandoxatrilThe serum concentration of Digoxin can be increased when it is combined with Candoxatril.
CapecitabineDigoxin may decrease the cardiotoxic activities of Capecitabine.
CaptoprilThe serum concentration of Digoxin can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Digoxin can be decreased when it is combined with Carbamazepine.
CarbimazoleThe serum concentration of Digoxin can be increased when it is combined with Carbimazole.
CarboplatinDigoxin may decrease the cardiotoxic activities of Carboplatin.
CarfilzomibDigoxin may decrease the cardiotoxic activities of Carfilzomib.
CarmofurDigoxin may decrease the cardiotoxic activities of Carmofur.
CarmustineDigoxin may decrease the cardiotoxic activities of Carmustine.
CarprofenThe serum concentration of Digoxin can be increased when it is combined with Carprofen.
CarteololCarteolol may increase the bradycardic activities of Digoxin.
CarvedilolDigoxin may increase the bradycardic activities of Carvedilol.
CaspofunginThe serum concentration of Digoxin can be increased when it is combined with Caspofungin.
CastanospermineThe serum concentration of Digoxin can be increased when it is combined with Castanospermine.
CatumaxomabDigoxin may decrease the cardiotoxic activities of Catumaxomab.
CB1954Digoxin may decrease the cardiotoxic activities of CB1954.
CelecoxibThe serum concentration of Digoxin can be increased when it is combined with Celecoxib.
CelecoxibDigoxin may decrease the cardiotoxic activities of Celecoxib.
CeliprololCeliprolol may increase the bradycardic activities of Digoxin.
CeritinibDigoxin may increase the bradycardic activities of Ceritinib.
CeritinibThe serum concentration of Digoxin can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Digoxin.
CetuximabDigoxin may decrease the cardiotoxic activities of Cetuximab.
ChlorambucilDigoxin may decrease the cardiotoxic activities of Chlorambucil.
ChloroquineThe serum concentration of Digoxin can be increased when it is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin.
ChlorotrianiseneDigoxin may decrease the cardiotoxic activities of Chlorotrianisene.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Digoxin.
ChlorpromazineThe serum concentration of Digoxin can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Digoxin can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Digoxin can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digoxin.
CholesterolThe serum concentration of Digoxin can be increased when it is combined with Cholesterol.
CholestyramineCholestyramine can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic AcidThe serum concentration of Digoxin can be decreased when it is combined with Cholic Acid.
ChymostatinThe serum concentration of Digoxin can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Digoxin can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Digoxin can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Digoxin.
CinoxacinDigoxin may decrease the cardiotoxic activities of Cinoxacin.
CiprofloxacinDigoxin may decrease the cardiotoxic activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Digoxin can be increased when it is combined with Ciprofloxacin.
CisplatinDigoxin may decrease the cardiotoxic activities of Cisplatin.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Digoxin.
CitalopramThe serum concentration of Digoxin can be increased when it is combined with Citalopram.
CladribineDigoxin may decrease the cardiotoxic activities of Cladribine.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Digoxin.
ClarithromycinThe serum concentration of Digoxin can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Digoxin can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Digoxin.
ClofarabineDigoxin may decrease the cardiotoxic activities of Clofarabine.
ClofazimineThe serum concentration of Digoxin can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Digoxin.
ClomipramineThe serum concentration of Digoxin can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Digoxin.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Digoxin.
ClonixinThe serum concentration of Digoxin can be increased when it is combined with Clonixin.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Digoxin.
ClotrimazoleThe metabolism of Digoxin can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Digoxin.
CobicistatThe serum concentration of Digoxin can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Digoxin.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Digoxin.
ColesevelamColesevelam can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Digoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColforsinThe serum concentration of Digoxin can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Digoxin can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Digoxin.
CrizotinibDigoxin may decrease the cardiotoxic activities of Crizotinib.
CrizotinibThe metabolism of Digoxin can be decreased when combined with Crizotinib.
CyclophosphamideDigoxin may decrease the cardiotoxic activities of Cyclophosphamide.
CyclophosphamideThe serum concentration of Digoxin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Digoxin can be increased when it is combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Digoxin.
Cyproterone acetateDigoxin may decrease the cardiotoxic activities of Cyproterone acetate.
CytarabineDigoxin may decrease the cardiotoxic activities of Cytarabine.
D-LimoneneThe serum concentration of Digoxin can be increased when it is combined with D-Limonene.
Dabigatran etexilateThe serum concentration of Digoxin can be increased when it is combined with Dabigatran etexilate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Digoxin.
DabrafenibDigoxin may decrease the cardiotoxic activities of Dabrafenib.
DabrafenibThe serum concentration of Digoxin can be decreased when it is combined with Dabrafenib.
DacarbazineDigoxin may decrease the cardiotoxic activities of Dacarbazine.
DaclatasvirThe serum concentration of Digoxin can be increased when it is combined with Daclatasvir.
DactinomycinDigoxin may decrease the cardiotoxic activities of Dactinomycin.
DactinomycinThe serum concentration of Digoxin can be increased when it is combined with Dactinomycin.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Digoxin.
DaratumumabDigoxin may decrease the cardiotoxic activities of Daratumumab.
DarunavirThe serum concentration of Digoxin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Digoxin can be increased when it is combined with Dasatinib.
DasatinibDigoxin may decrease the cardiotoxic activities of Dasatinib.
DaunorubicinDigoxin may decrease the cardiotoxic activities of Daunorubicin.
DaunorubicinThe serum concentration of Digoxin can be decreased when it is combined with Daunorubicin.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Digoxin.
DecitabineDigoxin may decrease the cardiotoxic activities of Decitabine.
DeferasiroxThe serum concentration of Digoxin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Digoxin can be decreased when combined with Delavirdine.
Denileukin diftitoxDigoxin may decrease the cardiotoxic activities of Denileukin diftitox.
DesipramineThe serum concentration of Digoxin can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Digoxin can be increased when it is combined with Desloratadine.
DexamethasoneDigoxin may decrease the cardiotoxic activities of Dexamethasone.
DexamethasoneThe serum concentration of Digoxin can be decreased when it is combined with Dexamethasone.
DexmedetomidineDigoxin may increase the bradycardic activities of Dexmedetomidine.
DexrazoxaneDigoxin may decrease the cardiotoxic activities of Dexrazoxane.
DextromethorphanThe serum concentration of Digoxin can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Digoxin.
DiclofenacThe serum concentration of Digoxin can be increased when it is combined with Diclofenac.
DienogestDigoxin may decrease the cardiotoxic activities of Dienogest.
DiethylstilbestrolDigoxin may decrease the cardiotoxic activities of Diethylstilbestrol.
DiflunisalThe serum concentration of Digoxin can be increased when it is combined with Diflunisal.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Digoxin can be decreased when combined with Dihydroergotamine.
DihydrostreptomycinThe serum concentration of Digoxin can be decreased when it is combined with Dihydrostreptomycin.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Digoxin.
DiltiazemThe metabolism of Digoxin can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Digoxin.
DinutuximabDigoxin may decrease the cardiotoxic activities of Dinutuximab.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Digoxin.
DipyridamoleThe serum concentration of Digoxin can be increased when it is combined with Dipyridamole.
DocetaxelDigoxin may decrease the cardiotoxic activities of Docetaxel.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Digoxin.
DonepezilDigoxin may increase the bradycardic activities of Donepezil.
DoxazosinThe serum concentration of Digoxin can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Digoxin can be increased when it is combined with Doxepin.
DoxorubicinDigoxin may decrease the cardiotoxic activities of Doxorubicin.
DoxorubicinThe serum concentration of Digoxin can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Digoxin can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Digoxin can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Digoxin can be decreased when combined with Dronedarone.
DronedaroneDigoxin may increase the bradycardic activities of Dronedarone.
DroxicamThe serum concentration of Digoxin can be increased when it is combined with Droxicam.
EcabetThe serum concentration of Digoxin can be increased when it is combined with Ecabet.
EcabetDigoxin may decrease the cardiotoxic activities of Ecabet.
EdoxabanThe serum concentration of Digoxin can be increased when it is combined with Edoxaban.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Digoxin.
EdrophoniumEdrophonium may increase the atrioventricular blocking (AV block) activities of Digoxin.
efaproxiralDigoxin may decrease the cardiotoxic activities of efaproxiral.
EfavirenzThe serum concentration of Digoxin can be decreased when it is combined with Efavirenz.
EflornithineDigoxin may decrease the cardiotoxic activities of Eflornithine.
EG009Digoxin may decrease the cardiotoxic activities of EG009.
ElafinThe serum concentration of Digoxin can be increased when it is combined with Elafin.
ElbasvirThe serum concentration of Digoxin can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Digoxin.
EliglustatThe serum concentration of Digoxin can be increased when it is combined with Eliglustat.
ElsamitrucinDigoxin may decrease the cardiotoxic activities of Elsamitrucin.
EltrombopagThe serum concentration of Digoxin can be increased when it is combined with Eltrombopag.
EnalaprilThe serum concentration of Digoxin can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Digoxin can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Digoxin can be increased when it is combined with Enalkiren.
EndostatinDigoxin may decrease the cardiotoxic activities of Endostatin.
EnoxacinDigoxin may decrease the cardiotoxic activities of Enoxacin.
EnrofloxacinDigoxin may decrease the cardiotoxic activities of Enrofloxacin.
EnzalutamideThe serum concentration of Digoxin can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Digoxin.
EpirizoleThe serum concentration of Digoxin can be increased when it is combined with Epirizole.
EpirubicinDigoxin may decrease the cardiotoxic activities of Epirubicin.
EpirubicinThe serum concentration of Digoxin can be decreased when it is combined with Epirubicin.
EplerenoneThe therapeutic efficacy of Digoxin can be decreased when used in combination with Eplerenone.
EpoprostenolThe serum concentration of Digoxin can be increased when it is combined with Epoprostenol.
Epothilone BDigoxin may decrease the cardiotoxic activities of Epothilone B.
ErgonovineThe serum concentration of Digoxin can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Digoxin can be increased when it is combined with Ergotamine.
EribulinDigoxin may decrease the cardiotoxic activities of Eribulin.
ErlotinibDigoxin may decrease the cardiotoxic activities of Erlotinib.
ErythromycinThe metabolism of Digoxin can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Digoxin.
Eslicarbazepine acetateThe serum concentration of Digoxin can be decreased when it is combined with Eslicarbazepine acetate.
EsmololEsmolol may increase the bradycardic activities of Digoxin.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Digoxin.
EstramustineDigoxin may decrease the cardiotoxic activities of Estramustine.
EstramustineThe serum concentration of Digoxin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Digoxin.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Digoxin.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin.
EtanerceptThe serum concentration of Digoxin can be increased when it is combined with Etanercept.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Digoxin.
Ethiodized oilDigoxin may decrease the cardiotoxic activities of Ethiodized oil.
Ethyl carbamateDigoxin may decrease the cardiotoxic activities of Ethyl carbamate.
EtodolacThe serum concentration of Digoxin can be increased when it is combined with Etodolac.
EtofenamateThe serum concentration of Digoxin can be increased when it is combined with Etofenamate.
EtoposideDigoxin may decrease the cardiotoxic activities of Etoposide.
EtoposideThe serum concentration of Digoxin can be increased when it is combined with Etoposide.
EtoricoxibThe serum concentration of Digoxin can be increased when it is combined with Etoricoxib.
EtravirineThe serum concentration of Digoxin can be increased when it is combined with Etravirine.
Evening primrose oilThe serum concentration of Digoxin can be increased when it is combined with Evening primrose oil.
EverolimusDigoxin may decrease the cardiotoxic activities of Everolimus.
ExemestaneDigoxin may decrease the cardiotoxic activities of Exemestane.
exisulindThe serum concentration of Digoxin can be increased when it is combined with exisulind.
exisulindDigoxin may decrease the cardiotoxic activities of exisulind.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Digoxin.
FelodipineThe serum concentration of Digoxin can be increased when it is combined with Felodipine.
FenbufenThe serum concentration of Digoxin can be increased when it is combined with Fenbufen.
FenoprofenThe serum concentration of Digoxin can be increased when it is combined with Fenoprofen.
FenretinideDigoxin may decrease the cardiotoxic activities of Fenretinide.
FentanylThe serum concentration of Digoxin can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Digoxin.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Digoxin.
FexofenadineThe serum concentration of Digoxin can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Digoxin.
FidaxomicinThe serum concentration of Digoxin can be increased when it is combined with Fidaxomicin.
FingolimodDigoxin may increase the bradycardic activities of Fingolimod.
FlavopiridolDigoxin may decrease the cardiotoxic activities of Flavopiridol.
FlecainideThe serum concentration of Digoxin can be increased when it is combined with Flecainide.
FleroxacinDigoxin may decrease the cardiotoxic activities of Fleroxacin.
FlibanserinThe serum concentration of Digoxin can be increased when it is combined with Flibanserin.
FloctafenineThe serum concentration of Digoxin can be increased when it is combined with Floctafenine.
FloxuridineDigoxin may decrease the cardiotoxic activities of Floxuridine.
FluconazoleThe metabolism of Digoxin can be decreased when combined with Fluconazole.
FludarabineDigoxin may decrease the cardiotoxic activities of Fludarabine.
FlumequineDigoxin may decrease the cardiotoxic activities of Flumequine.
FlunixinThe serum concentration of Digoxin can be increased when it is combined with Flunixin.
FluorouracilDigoxin may decrease the cardiotoxic activities of Fluorouracil.
FluoxetineThe serum concentration of Digoxin can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Digoxin can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Digoxin can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Digoxin can be increased when it is combined with Flurazepam.
FlurbiprofenThe serum concentration of Digoxin can be increased when it is combined with Flurbiprofen.
FlutamideDigoxin may decrease the cardiotoxic activities of Flutamide.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Digoxin.
FluvoxamineThe metabolism of Digoxin can be decreased when combined with Fluvoxamine.
FormestaneDigoxin may decrease the cardiotoxic activities of Formestane.
FormycinDigoxin may decrease the cardiotoxic activities of Formycin.
FosamprenavirThe serum concentration of Digoxin can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Digoxin can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Digoxin can be increased when it is combined with Fosinopril.
FosphenytoinThe metabolism of Digoxin can be increased when combined with Fosphenytoin.
FotemustineDigoxin may decrease the cardiotoxic activities of Fotemustine.
FramycetinThe serum concentration of Digoxin can be decreased when it is combined with Framycetin.
FulvestrantDigoxin may decrease the cardiotoxic activities of Fulvestrant.
FumagillinDigoxin may decrease the cardiotoxic activities of Fumagillin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Digoxin.
Fusidic AcidThe serum concentration of Digoxin can be increased when it is combined with Fusidic Acid.
GalantamineDigoxin may increase the bradycardic activities of Galantamine.
Gallium nitrateDigoxin may decrease the cardiotoxic activities of Gallium nitrate.
GarenoxacinDigoxin may decrease the cardiotoxic activities of Garenoxacin.
GatifloxacinDigoxin may decrease the cardiotoxic activities of Gatifloxacin.
GefitinibDigoxin may decrease the cardiotoxic activities of Gefitinib.
GefitinibThe serum concentration of Digoxin can be increased when it is combined with Gefitinib.
GeldanamycinThe serum concentration of Digoxin can be increased when it is combined with Geldanamycin.
GeldanamycinDigoxin may decrease the cardiotoxic activities of Geldanamycin.
GemcitabineDigoxin may decrease the cardiotoxic activities of Gemcitabine.
GemifloxacinDigoxin may decrease the cardiotoxic activities of Gemifloxacin.
Gemtuzumab ozogamicinDigoxin may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.
GenisteinDigoxin may decrease the cardiotoxic activities of Genistein.
GenisteinThe serum concentration of Digoxin can be increased when it is combined with Genistein.
GentamicinThe serum concentration of Digoxin can be decreased when it is combined with Gentamicin.
Ginsenoside CDigoxin may decrease the cardiotoxic activities of Ginsenoside C.
GlyburideThe serum concentration of Digoxin can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Digoxin can be increased when it is combined with Glycerol.
GlycopyrroniumThe serum concentration of Digoxin can be increased when it is combined with Glycopyrronium.
GM6001The serum concentration of Digoxin can be increased when it is combined with GM6001.
GoserelinDigoxin may decrease the cardiotoxic activities of Goserelin.
Gramicidin DThe serum concentration of Digoxin can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Digoxin.
GrepafloxacinDigoxin may decrease the cardiotoxic activities of Grepafloxacin.
GrepafloxacinThe serum concentration of Digoxin can be increased when it is combined with Grepafloxacin.
GuanfacineDigoxin may increase the bradycardic activities of Guanfacine.
HadacidinDigoxin may decrease the cardiotoxic activities of Hadacidin.
HalofuginoneDigoxin may decrease the cardiotoxic activities of Halofuginone.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Digoxin.
HaloperidolThe serum concentration of Digoxin can be increased when it is combined with Haloperidol.
HexestrolDigoxin may decrease the cardiotoxic activities of Hexestrol.
HirulogThe serum concentration of Digoxin can be increased when it is combined with Hirulog.
HMPL-004The serum concentration of Digoxin can be increased when it is combined with HMPL-004.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Digoxin.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Digoxin.
HydrocortisoneThe serum concentration of Digoxin can be increased when it is combined with Hydrocortisone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin.
HydroxychloroquineThe serum concentration of Digoxin can be increased when it is combined with Hydroxychloroquine.
Hydroxyprogesterone caproateDigoxin may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.
HydroxyureaDigoxin may decrease the cardiotoxic activities of Hydroxyurea.
Hygromycin BThe serum concentration of Digoxin can be decreased when it is combined with Hygromycin B.
IbrutinibDigoxin may decrease the cardiotoxic activities of Ibrutinib.
IbuprofenThe serum concentration of Digoxin can be increased when it is combined with Ibuprofen.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Digoxin.
IbuproxamThe serum concentration of Digoxin can be increased when it is combined with Ibuproxam.
IcatibantThe serum concentration of Digoxin can be increased when it is combined with Icatibant.
IdarubicinDigoxin may decrease the cardiotoxic activities of Idarubicin.
IdarubicinThe serum concentration of Digoxin can be decreased when it is combined with Idarubicin.
IdelalisibThe serum concentration of Digoxin can be increased when it is combined with Idelalisib.
IdelalisibDigoxin may decrease the cardiotoxic activities of Idelalisib.
IfosfamideDigoxin may decrease the cardiotoxic activities of Ifosfamide.
ImatinibDigoxin may decrease the cardiotoxic activities of Imatinib.
ImatinibThe metabolism of Digoxin can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Digoxin.
ImipramineThe serum concentration of Digoxin can be increased when it is combined with Imipramine.
ImiquimodDigoxin may decrease the cardiotoxic activities of Imiquimod.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Digoxin.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Digoxin.
IndenololIndenolol may increase the bradycardic activities of Digoxin.
IndinavirThe serum concentration of Digoxin can be increased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Digoxin.
IndomethacinThe serum concentration of Digoxin can be increased when it is combined with Indomethacin.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Digoxin.
IndoprofenThe serum concentration of Digoxin can be increased when it is combined with Indoprofen.
Interferon beta-1aDigoxin may decrease the cardiotoxic activities of Interferon beta-1a.
IobenguaneDigoxin may decrease the cardiotoxic activities of Iobenguane.
IpilimumabDigoxin may decrease the cardiotoxic activities of Ipilimumab.
IrinotecanDigoxin may decrease the cardiotoxic activities of Irinotecan.
IsavuconazoniumThe serum concentration of Digoxin can be increased when it is combined with Isavuconazonium.
IsoflurophateThe serum concentration of Digoxin can be increased when it is combined with Isoflurophate.
IsoxicamThe serum concentration of Digoxin can be increased when it is combined with Isoxicam.
IsradipineThe metabolism of Digoxin can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Digoxin can be increased when it is combined with Itraconazole.
IvabradineDigoxin may increase the bradycardic activities of Ivabradine.
IvacaftorThe serum concentration of Digoxin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Digoxin.
IvermectinThe serum concentration of Digoxin can be increased when it is combined with Ivermectin.
IxabepiloneDigoxin may decrease the cardiotoxic activities of Ixabepilone.
IxazomibThe serum concentration of Digoxin can be increased when it is combined with Ixazomib.
IxazomibDigoxin may decrease the cardiotoxic activities of Ixazomib.
KanamycinThe serum concentration of Digoxin can be decreased when it is combined with Kanamycin.
KaolinThe serum concentration of Digoxin can be decreased when it is combined with Kaolin.
KebuzoneThe serum concentration of Digoxin can be increased when it is combined with Kebuzone.
KetamineThe serum concentration of Digoxin can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Digoxin.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Digoxin.
KetoconazoleThe serum concentration of Digoxin can be increased when it is combined with Ketoconazole.
KetoprofenThe serum concentration of Digoxin can be increased when it is combined with Ketoprofen.
KetorolacThe serum concentration of Digoxin can be increased when it is combined with Ketorolac.
KOS-1584Digoxin may decrease the cardiotoxic activities of KOS-1584.
L-alanosineDigoxin may decrease the cardiotoxic activities of L-alanosine.
LabetalolLabetalol may increase the bradycardic activities of Digoxin.
LacosamideDigoxin may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Digoxin.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Digoxin.
LanreotideDigoxin may decrease the cardiotoxic activities of Lanreotide.
LanreotideLanreotide may increase the bradycardic activities of Digoxin.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Digoxin.
LansoprazoleThe serum concentration of Digoxin can be increased when it is combined with Lansoprazole.
LapatinibDigoxin may decrease the cardiotoxic activities of Lapatinib.
LapatinibThe serum concentration of Digoxin can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Digoxin.
LeflunomideThe serum concentration of Digoxin can be increased when it is combined with Leflunomide.
LeflunomideDigoxin may decrease the cardiotoxic activities of Leflunomide.
LenalidomideThe serum concentration of Digoxin can be increased when it is combined with Lenalidomide.
LenalidomideDigoxin may decrease the cardiotoxic activities of Lenalidomide.
LenvatinibDigoxin may decrease the cardiotoxic activities of Lenvatinib.
LepirudinThe serum concentration of Digoxin can be increased when it is combined with Lepirudin.
LetrozoleDigoxin may decrease the cardiotoxic activities of Letrozole.
LeuprolideDigoxin may decrease the cardiotoxic activities of Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Digoxin.
LevobunololLevobunolol may increase the bradycardic activities of Digoxin.
LevofloxacinDigoxin may decrease the cardiotoxic activities of Levofloxacin.
LevofloxacinThe serum concentration of Digoxin can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Digoxin.
LevothyroxineThe serum concentration of Digoxin can be decreased when it is combined with Levothyroxine.
LicoriceThe risk or severity of adverse effects can be increased when Licorice is combined with Digoxin.
LidocaineThe serum concentration of Digoxin can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Digoxin can be increased when it is combined with Linagliptin.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Digoxin.
LiothyronineThe serum concentration of Digoxin can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Digoxin can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Digoxin can be increased when it is combined with Lisinopril.
LomefloxacinDigoxin may decrease the cardiotoxic activities of Lomefloxacin.
LomitapideThe serum concentration of Digoxin can be increased when it is combined with Lomitapide.
LomustineDigoxin may decrease the cardiotoxic activities of Lomustine.
LonidamineDigoxin may decrease the cardiotoxic activities of Lonidamine.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Digoxin.
LoperamideThe serum concentration of Digoxin can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Digoxin can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Digoxin can be increased when it is combined with Loratadine.
LornoxicamThe serum concentration of Digoxin can be increased when it is combined with Lornoxicam.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Digoxin.
LosartanThe serum concentration of Digoxin can be increased when it is combined with Losartan.
LovastatinThe metabolism of Digoxin can be decreased when combined with Lovastatin.
LoxoprofenThe serum concentration of Digoxin can be increased when it is combined with Loxoprofen.
LucinactantDigoxin may increase the bradycardic activities of Lucinactant.
LuliconazoleThe serum concentration of Digoxin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Digoxin can be decreased when it is combined with Lumacaftor.
LumiracoxibThe serum concentration of Digoxin can be increased when it is combined with Lumiracoxib.
LycopeneDigoxin may decrease the cardiotoxic activities of Lycopene.
Magnesium salicylateThe serum concentration of Digoxin can be increased when it is combined with Magnesium salicylate.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Digoxin.
MaprotilineThe serum concentration of Digoxin can be increased when it is combined with Maprotiline.
MasitinibDigoxin may decrease the cardiotoxic activities of Masitinib.
MasoprocolThe serum concentration of Digoxin can be increased when it is combined with Masoprocol.
MasoprocolDigoxin may decrease the cardiotoxic activities of Masoprocol.
MaxacalcitolDigoxin may decrease the cardiotoxic activities of Maxacalcitol.
MDX-1106Digoxin may decrease the cardiotoxic activities of MDX-1106.
MebendazoleDigoxin may decrease the cardiotoxic activities of Mebendazole.
MebendazoleThe serum concentration of Digoxin can be increased when it is combined with Mebendazole.
MechlorethamineDigoxin may decrease the cardiotoxic activities of Mechlorethamine.
Meclofenamic acidThe serum concentration of Digoxin can be increased when it is combined with Meclofenamic acid.
MedrogestoneDigoxin may decrease the cardiotoxic activities of Medrogestone.
Medroxyprogesterone acetateDigoxin may decrease the cardiotoxic activities of Medroxyprogesterone acetate.
Mefenamic acidThe serum concentration of Digoxin can be increased when it is combined with Mefenamic acid.
MefloquineThe serum concentration of Digoxin can be increased when it is combined with Mefloquine.
Megestrol acetateDigoxin may decrease the cardiotoxic activities of Megestrol acetate.
Megestrol acetateThe serum concentration of Digoxin can be increased when it is combined with Megestrol acetate.
MeloxicamThe serum concentration of Digoxin can be increased when it is combined with Meloxicam.
MelphalanDigoxin may decrease the cardiotoxic activities of Melphalan.
MeprobamateThe serum concentration of Digoxin can be increased when it is combined with Meprobamate.
MequinolDigoxin may decrease the cardiotoxic activities of Mequinol.
MercaptopurineDigoxin may decrease the cardiotoxic activities of Mercaptopurine.
MesalazineThe serum concentration of Digoxin can be increased when it is combined with Mesalazine.
MetamizoleThe serum concentration of Digoxin can be increased when it is combined with Metamizole.
MethadoneThe serum concentration of Digoxin can be increased when it is combined with Methadone.
MethimazoleThe serum concentration of Digoxin can be increased when it is combined with Methimazole.
MethotrexateDigoxin may decrease the cardiotoxic activities of Methotrexate.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin.
Methyl aminolevulinateDigoxin may decrease the cardiotoxic activities of Methyl aminolevulinate.
MethyldopaDigoxin may increase the bradycardic activities of Methyldopa.
MethylprednisoloneDigoxin may decrease the cardiotoxic activities of Methylprednisolone.
MethyltestosteroneDigoxin may decrease the cardiotoxic activities of Methyltestosterone.
MetipranololMetipranolol may increase the bradycardic activities of Digoxin.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Digoxin.
MetoprololMetoprolol may increase the bradycardic activities of Digoxin.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Digoxin.
MetrizamideThe serum concentration of Digoxin can be decreased when it is combined with Metrizamide.
MGI-114Digoxin may decrease the cardiotoxic activities of MGI-114.
MibefradilThe serum concentration of Digoxin can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Digoxin can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Digoxin.
MidodrineDigoxin may increase the bradycardic activities of Midodrine.
MidostaurinDigoxin may decrease the cardiotoxic activities of Midostaurin.
MifepristoneThe serum concentration of Digoxin can be increased when it is combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Digoxin.
MiltefosineDigoxin may decrease the cardiotoxic activities of Miltefosine.
MirabegronThe serum concentration of Digoxin can be increased when it is combined with Mirabegron.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Digoxin.
MitomycinDigoxin may decrease the cardiotoxic activities of Mitomycin.
MitomycinThe serum concentration of Digoxin can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Digoxin can be decreased when it is combined with Mitotane.
MitotaneDigoxin may decrease the cardiotoxic activities of Mitotane.
MitoxantroneDigoxin may decrease the cardiotoxic activities of Mitoxantrone.
MitoxantroneThe serum concentration of Digoxin can be decreased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Digoxin can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Digoxin can be increased when it is combined with Moexipril.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Digoxin.
MorphineThe serum concentration of Digoxin can be increased when it is combined with Morphine.
motexafin gadoliniumDigoxin may decrease the cardiotoxic activities of motexafin gadolinium.
MoxifloxacinDigoxin may decrease the cardiotoxic activities of Moxifloxacin.
Mycophenolate mofetilThe serum concentration of Digoxin can be increased when it is combined with Mycophenolate mofetil.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Digoxin.
Mycophenolic acidThe serum concentration of Digoxin can be increased when it is combined with Mycophenolic acid.
Mycophenolic acidDigoxin may decrease the cardiotoxic activities of Mycophenolic acid.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Digoxin can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabumetoneThe serum concentration of Digoxin can be increased when it is combined with Nabumetone.
NadololNadolol may increase the bradycardic activities of Digoxin.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Digoxin.
NafcillinThe serum concentration of Digoxin can be decreased when it is combined with Nafcillin.
NaftifineThe serum concentration of Digoxin can be increased when it is combined with Naftifine.
Nalidixic AcidDigoxin may decrease the cardiotoxic activities of Nalidixic Acid.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Digoxin.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Digoxin.
NaltrexoneThe serum concentration of Digoxin can be increased when it is combined with Naltrexone.
NaproxenThe serum concentration of Digoxin can be increased when it is combined with Naproxen.
NaringeninThe serum concentration of Digoxin can be increased when it is combined with Naringenin.
NCX 4016The serum concentration of Digoxin can be increased when it is combined with NCX 4016.
NebivololDigoxin may increase the bradycardic activities of Nebivolol.
NecitumumabDigoxin may decrease the cardiotoxic activities of Necitumumab.
NefazodoneThe serum concentration of Digoxin can be increased when it is combined with Nefazodone.
NelarabineDigoxin may decrease the cardiotoxic activities of Nelarabine.
NelfinavirThe serum concentration of Digoxin can be increased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Digoxin.
NeomycinThe serum concentration of Digoxin can be decreased when it is combined with Neomycin.
NeostigmineThe serum concentration of Digoxin can be increased when it is combined with Neostigmine.
NepafenacThe serum concentration of Digoxin can be increased when it is combined with Nepafenac.
NetilmicinThe serum concentration of Digoxin can be decreased when it is combined with Netilmicin.
NetupitantThe serum concentration of Digoxin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Digoxin can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Digoxin.
NicardipineThe serum concentration of Digoxin can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Digoxin can be increased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Digoxin.
Niflumic AcidThe serum concentration of Digoxin can be increased when it is combined with Niflumic Acid.
NiguldipineDigoxin may decrease the cardiotoxic activities of Niguldipine.
NilotinibDigoxin may decrease the cardiotoxic activities of Nilotinib.
NilotinibThe metabolism of Digoxin can be decreased when combined with Nilotinib.
NilutamideDigoxin may decrease the cardiotoxic activities of Nilutamide.
NimesulideThe serum concentration of Digoxin can be increased when it is combined with Nimesulide.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Digoxin.
NisoldipineThe serum concentration of Digoxin can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Digoxin can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Digoxin can be increased when it is combined with Nitrendipine.
NivolumabDigoxin may decrease the cardiotoxic activities of Nivolumab.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Digoxin.
nocodazoleDigoxin may decrease the cardiotoxic activities of nocodazole.
NorethisteroneThe serum concentration of Digoxin can be decreased when it is combined with Norethisterone.
NorfloxacinDigoxin may decrease the cardiotoxic activities of Norfloxacin.
ObinutuzumabDigoxin may decrease the cardiotoxic activities of Obinutuzumab.
OctreotideDigoxin may decrease the cardiotoxic activities of Octreotide.
OctreotideOctreotide may increase the bradycardic activities of Digoxin.
OfatumumabDigoxin may decrease the cardiotoxic activities of Ofatumumab.
OfloxacinDigoxin may decrease the cardiotoxic activities of Ofloxacin.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Digoxin.
OlaparibDigoxin may decrease the cardiotoxic activities of Olaparib.
OlaparibThe metabolism of Digoxin can be decreased when combined with Olaparib.
OlopatadineThe serum concentration of Digoxin can be increased when it is combined with Olopatadine.
OlsalazineThe serum concentration of Digoxin can be increased when it is combined with Olsalazine.
Omacetaxine mepesuccinateDigoxin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.
OmapatrilatThe serum concentration of Digoxin can be increased when it is combined with Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Digoxin.
OmeprazoleThe serum concentration of Digoxin can be increased when it is combined with Omeprazole.
OprelvekinDigoxin may decrease the cardiotoxic activities of Oprelvekin.
OrgoteinThe serum concentration of Digoxin can be increased when it is combined with Orgotein.
OsimertinibThe serum concentration of Digoxin can be increased when it is combined with Osimertinib.
OsimertinibDigoxin may decrease the cardiotoxic activities of Osimertinib.
OtamixabanThe serum concentration of Digoxin can be increased when it is combined with Otamixaban.
OxaliplatinDigoxin may decrease the cardiotoxic activities of Oxaliplatin.
OxaprozinThe serum concentration of Digoxin can be increased when it is combined with Oxaprozin.
OxprenololOxprenolol may increase the bradycardic activities of Digoxin.
OxyphenbutazoneThe serum concentration of Digoxin can be increased when it is combined with Oxyphenbutazone.
P-NitrophenolThe serum concentration of Digoxin can be increased when it is combined with P-Nitrophenol.
PaclitaxelDigoxin may decrease the cardiotoxic activities of Paclitaxel.
PaclitaxelThe serum concentration of Digoxin can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Digoxin can be increased when it is combined with Palbociclib.
PalbociclibDigoxin may decrease the cardiotoxic activities of Palbociclib.
PalifosfamideDigoxin may decrease the cardiotoxic activities of Palifosfamide.
Palmitic AcidThe serum concentration of Digoxin can be increased when it is combined with Palmitic Acid.
PamidronateDigoxin may decrease the cardiotoxic activities of Pamidronate.
PanitumumabDigoxin may decrease the cardiotoxic activities of Panitumumab.
PanobinostatDigoxin may decrease the cardiotoxic activities of Panobinostat.
PantoprazoleThe serum concentration of Digoxin can be increased when it is combined with Pantoprazole.
Parathyroid hormoneThe risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digoxin.
ParecoxibThe serum concentration of Digoxin can be increased when it is combined with Parecoxib.
ParicalcitolThe risk or severity of adverse effects can be increased when Paricalcitol is combined with Digoxin.
ParomomycinThe serum concentration of Digoxin can be decreased when it is combined with Paromomycin.
ParoxetineThe serum concentration of Digoxin can be increased when it is combined with Paroxetine.
PasireotideDigoxin may increase the bradycardic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Digoxin.
PefloxacinDigoxin may decrease the cardiotoxic activities of Pefloxacin.
PegaspargaseDigoxin may decrease the cardiotoxic activities of Pegaspargase.
PembrolizumabDigoxin may decrease the cardiotoxic activities of Pembrolizumab.
PemetrexedDigoxin may decrease the cardiotoxic activities of Pemetrexed.
PenbutololPenbutolol may increase the bradycardic activities of Digoxin.
PenicillamineThe serum concentration of Digoxin can be decreased when it is combined with Penicillamine.
PentobarbitalThe metabolism of Digoxin can be increased when combined with Pentobarbital.
PentostatinDigoxin may decrease the cardiotoxic activities of Pentostatin.
PerindoprilThe serum concentration of Digoxin can be increased when it is combined with Perindopril.
PertuzumabDigoxin may decrease the cardiotoxic activities of Pertuzumab.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Digoxin.
Phenylacetic acidDigoxin may decrease the cardiotoxic activities of Phenylacetic acid.
PhenylbutazoneThe serum concentration of Digoxin can be increased when it is combined with Phenylbutazone.
PhenytoinThe metabolism of Digoxin can be increased when combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Digoxin.
PhosphoramidonThe serum concentration of Digoxin can be increased when it is combined with Phosphoramidon.
PimecrolimusThe serum concentration of Digoxin can be increased when it is combined with Pimecrolimus.
PimozideThe serum concentration of Digoxin can be increased when it is combined with Pimozide.
PindololPindolol may increase the bradycardic activities of Digoxin.
PipobromanDigoxin may decrease the cardiotoxic activities of Pipobroman.
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Digoxin.
PirfenidoneThe serum concentration of Digoxin can be increased when it is combined with Pirfenidone.
PirfenidoneDigoxin may decrease the cardiotoxic activities of Pirfenidone.
PirlindoleDigoxin may decrease the cardiotoxic activities of Pirlindole.
PiroxicamThe serum concentration of Digoxin can be increased when it is combined with Piroxicam.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Digoxin.
PixantroneDigoxin may decrease the cardiotoxic activities of Pixantrone.
Platelet Activating FactorThe serum concentration of Digoxin can be decreased when it is combined with Platelet Activating Factor.
PlicamycinDigoxin may decrease the cardiotoxic activities of Plicamycin.
PlicamycinThe serum concentration of Digoxin can be decreased when it is combined with Plicamycin.
PodofiloxDigoxin may decrease the cardiotoxic activities of Podofilox.
PodophyllinDigoxin may decrease the cardiotoxic activities of Podophyllin.
polyacrylic acidDigoxin may decrease the cardiotoxic activities of polyacrylic acid.
Polyethylene glycolThe serum concentration of Digoxin can be decreased when it is combined with Polyethylene glycol.
Polystyrene sulfonateThe risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Digoxin.
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Digoxin.
PomalidomideDigoxin may decrease the cardiotoxic activities of Pomalidomide.
PonatinibDigoxin may decrease the cardiotoxic activities of Ponatinib.
PonatinibThe serum concentration of Digoxin can be increased when it is combined with Ponatinib.
Poractant alfaDigoxin may increase the bradycardic activities of Poractant alfa.
PorfimerDigoxin may decrease the cardiotoxic activities of Porfimer.
porfiromycinDigoxin may decrease the cardiotoxic activities of porfiromycin.
PosaconazoleThe serum concentration of Digoxin can be increased when it is combined with Posaconazole.
PractololPractolol may increase the bradycardic activities of Digoxin.
PralatrexateDigoxin may decrease the cardiotoxic activities of Pralatrexate.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Digoxin.
PravastatinThe serum concentration of Digoxin can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Digoxin.
PrazosinThe serum concentration of Digoxin can be increased when it is combined with Prazosin.
PrednisoloneDigoxin may decrease the cardiotoxic activities of Prednisolone.
PrednisoneDigoxin may decrease the cardiotoxic activities of Prednisone.
PrednisoneThe serum concentration of Digoxin can be increased when it is combined with Prednisone.
PrimaquineThe serum concentration of Digoxin can be increased when it is combined with Primaquine.
PrimidoneThe metabolism of Digoxin can be increased when combined with Primidone.
PrinomastatThe serum concentration of Digoxin can be increased when it is combined with Prinomastat.
ProbenecidThe serum concentration of Digoxin can be increased when it is combined with Probenecid.
ProcarbazineDigoxin may decrease the cardiotoxic activities of Procarbazine.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Digoxin.
PromethazineThe serum concentration of Digoxin can be increased when it is combined with Promethazine.
PropacetamolThe serum concentration of Digoxin can be increased when it is combined with Propacetamol.
PropafenoneThe serum concentration of Digoxin can be increased when it is combined with Propafenone.
PropafenoneDigoxin may increase the bradycardic activities of Propafenone.
PropranololPropranolol may increase the bradycardic activities of Digoxin.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Digoxin.
PropylthiouracilThe serum concentration of Digoxin can be increased when it is combined with Propylthiouracil.
ProtriptylineThe serum concentration of Digoxin can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Digoxin.
PTC299The serum concentration of Digoxin can be increased when it is combined with PTC299.
Purine RibosideDigoxin may decrease the cardiotoxic activities of Purine Riboside.
PuromycinDigoxin may decrease the cardiotoxic activities of Puromycin.
PuromycinThe serum concentration of Digoxin can be decreased when it is combined with Puromycin.
QuercetinThe serum concentration of Digoxin can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Digoxin.
QuinacrineDigoxin may decrease the cardiotoxic activities of Quinacrine.
QuinacrineThe serum concentration of Digoxin can be increased when it is combined with Quinacrine.
QuinaprilThe serum concentration of Digoxin can be increased when it is combined with Quinapril.
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Digoxin.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Digoxin.
QuinidineThe serum concentration of Digoxin can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Digoxin can be increased when it is combined with Quinine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Digoxin.
Radium Ra 223 DichlorideDigoxin may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.
RaltitrexedDigoxin may decrease the cardiotoxic activities of Raltitrexed.
RamiprilThe serum concentration of Digoxin can be increased when it is combined with Ramipril.
RamucirumabDigoxin may decrease the cardiotoxic activities of Ramucirumab.
RanibizumabDigoxin may decrease the cardiotoxic activities of Ranibizumab.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Digoxin.
RanitidineThe serum concentration of Digoxin can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Digoxin.
RanpirnaseDigoxin may decrease the cardiotoxic activities of Ranpirnase.
ReboxetineThe serum concentration of Digoxin can be increased when it is combined with Reboxetine.
RegorafenibRegorafenib may increase the bradycardic activities of Digoxin.
RegorafenibDigoxin may decrease the cardiotoxic activities of Regorafenib.
RemikirenThe serum concentration of Digoxin can be increased when it is combined with Remikiren.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Digoxin.
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Digoxin.
ResveratrolThe serum concentration of Digoxin can be increased when it is combined with Resveratrol.
ResveratrolDigoxin may decrease the cardiotoxic activities of Resveratrol.
Rhodamine 6GDigoxin may decrease the cardiotoxic activities of Rhodamine 6G.
RibostamycinThe serum concentration of Digoxin can be decreased when it is combined with Ribostamycin.
RifabutinThe metabolism of Digoxin can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Digoxin can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Digoxin can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Digoxin.
RilpivirineThe serum concentration of Digoxin can be increased when it is combined with Rilpivirine.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Digoxin.
RitonavirThe serum concentration of Digoxin can be increased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Digoxin.
RituximabDigoxin may decrease the cardiotoxic activities of Rituximab.
RivaroxabanThe serum concentration of Digoxin can be increased when it is combined with Rivaroxaban.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Digoxin.
RivastigmineDigoxin may increase the bradycardic activities of Rivastigmine.
RofecoxibThe serum concentration of Digoxin can be increased when it is combined with Rofecoxib.
RolapitantThe serum concentration of Digoxin can be increased when it is combined with Rolapitant.
RomidepsinDigoxin may decrease the cardiotoxic activities of Romidepsin.
RomiplostimDigoxin may decrease the cardiotoxic activities of Romiplostim.
RoquinimexDigoxin may decrease the cardiotoxic activities of Roquinimex.
RubitecanDigoxin may decrease the cardiotoxic activities of Rubitecan.
RuxolitinibRuxolitinib may increase the bradycardic activities of Digoxin.
RuxolitinibDigoxin may decrease the cardiotoxic activities of Ruxolitinib.
SalicylamideThe serum concentration of Digoxin can be increased when it is combined with Salicylamide.
Salicylic acidThe serum concentration of Digoxin can be increased when it is combined with Salicylic acid.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Digoxin.
SalsalateThe serum concentration of Digoxin can be increased when it is combined with Salsalate.
SaquinavirThe serum concentration of Digoxin can be increased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Digoxin.
SatraplatinDigoxin may decrease the cardiotoxic activities of Satraplatin.
SaxagliptinThe serum concentration of Digoxin can be increased when it is combined with Saxagliptin.
ScopolamineThe serum concentration of Digoxin can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Digoxin can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Digoxin.
SeliciclibDigoxin may decrease the cardiotoxic activities of Seliciclib.
SemaxanibDigoxin may decrease the cardiotoxic activities of Semaxanib.
SeocalcitolDigoxin may decrease the cardiotoxic activities of Seocalcitol.
SeratrodastThe serum concentration of Digoxin can be increased when it is combined with Seratrodast.
SertralineThe serum concentration of Digoxin can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Digoxin can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Digoxin.
SiltuximabThe serum concentration of Digoxin can be decreased when it is combined with Siltuximab.
SiltuximabDigoxin may decrease the cardiotoxic activities of Siltuximab.
SimeprevirThe serum concentration of Digoxin can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Digoxin.
SimvastatinThe serum concentration of Digoxin can be increased when it is combined with Simvastatin.
SirolimusDigoxin may decrease the cardiotoxic activities of Sirolimus.
SirolimusThe serum concentration of Digoxin can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Digoxin can be increased when it is combined with Sitagliptin.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Digoxin.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Digoxin.
SonidegibDigoxin may decrease the cardiotoxic activities of Sonidegib.
SorafenibDigoxin may decrease the cardiotoxic activities of Sorafenib.
SorafenibThe serum concentration of Digoxin can be increased when it is combined with Sorafenib.
SotalolSotalol may increase the bradycardic activities of Digoxin.
SparfloxacinDigoxin may decrease the cardiotoxic activities of Sparfloxacin.
Sparfosic acidDigoxin may decrease the cardiotoxic activities of Sparfosic acid.
SparsomycinDigoxin may decrease the cardiotoxic activities of Sparsomycin.
SpectinomycinThe serum concentration of Digoxin can be decreased when it is combined with Spectinomycin.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Digoxin.
SpiraprilThe serum concentration of Digoxin can be increased when it is combined with Spirapril.
SpironolactoneThe serum concentration of Digoxin can be increased when it is combined with Spironolactone.
squalamineDigoxin may decrease the cardiotoxic activities of squalamine.
SRT501The serum concentration of Digoxin can be increased when it is combined with SRT501.
SRT501Digoxin may decrease the cardiotoxic activities of SRT501.
St. John's WortThe serum concentration of Digoxin can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Digoxin can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Digoxin can be increased when it is combined with Stiripentol.
StreptomycinThe serum concentration of Digoxin can be decreased when it is combined with Streptomycin.
StreptozocinDigoxin may decrease the cardiotoxic activities of Streptozocin.
StreptozocinThe serum concentration of Digoxin can be decreased when it is combined with Streptozocin.
SucralfateThe serum concentration of Digoxin can be decreased when it is combined with Sucralfate.
SufentanilDigoxin may increase the bradycardic activities of Sufentanil.
SulfasalazineThe serum concentration of Digoxin can be increased when it is combined with Sulfasalazine.
SulfinpyrazoneThe serum concentration of Digoxin can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Digoxin can be decreased when combined with Sulfisoxazole.
SulindacThe serum concentration of Digoxin can be increased when it is combined with Sulindac.
SulindacDigoxin may decrease the cardiotoxic activities of Sulindac.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Digoxin.
SumatriptanThe serum concentration of Digoxin can be increased when it is combined with Sumatriptan.
SunitinibDigoxin may decrease the cardiotoxic activities of Sunitinib.
SunitinibThe serum concentration of Digoxin can be increased when it is combined with Sunitinib.
SuprofenThe serum concentration of Digoxin can be increased when it is combined with Suprofen.
SuraminDigoxin may decrease the cardiotoxic activities of Suramin.
SwainsonineDigoxin may decrease the cardiotoxic activities of Swainsonine.
TacrineThe serum concentration of Digoxin can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Digoxin.
TamoxifenDigoxin may decrease the cardiotoxic activities of Tamoxifen.
TamoxifenThe serum concentration of Digoxin can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Digoxin.
Taurocholic AcidThe serum concentration of Digoxin can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Digoxin.
TegafurDigoxin may decrease the cardiotoxic activities of Tegafur.
TelaprevirThe serum concentration of Digoxin can be increased when it is combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Digoxin.
TelithromycinThe metabolism of Digoxin can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Digoxin can be increased when it is combined with Telmisartan.
TemafloxacinDigoxin may decrease the cardiotoxic activities of Temafloxacin.
TemocaprilThe serum concentration of Digoxin can be increased when it is combined with Temocapril.
TemozolomideDigoxin may decrease the cardiotoxic activities of Temozolomide.
TemsirolimusDigoxin may decrease the cardiotoxic activities of Temsirolimus.
TemsirolimusThe serum concentration of Digoxin can be increased when it is combined with Temsirolimus.
TeniposideDigoxin may decrease the cardiotoxic activities of Teniposide.
TenoxicamThe serum concentration of Digoxin can be increased when it is combined with Tenoxicam.
TepoxalinThe serum concentration of Digoxin can be increased when it is combined with Tepoxalin.
TerazosinThe serum concentration of Digoxin can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Digoxin can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Digoxin can be increased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Digoxin can be decreased when it is combined with Tesmilifene.
TestolactoneDigoxin may decrease the cardiotoxic activities of Testolactone.
TestosteroneThe serum concentration of Digoxin can be increased when it is combined with Testosterone.
TetrathiomolybdateDigoxin may decrease the cardiotoxic activities of Tetrathiomolybdate.
TezacitabineDigoxin may decrease the cardiotoxic activities of Tezacitabine.
ThalidomideDigoxin may decrease the cardiotoxic activities of Thalidomide.
ThiorphanThe serum concentration of Digoxin can be increased when it is combined with Thiorphan.
ThiotepaDigoxin may decrease the cardiotoxic activities of Thiotepa.
ThymalfasinDigoxin may decrease the cardiotoxic activities of Thymalfasin.
Tiaprofenic acidThe serum concentration of Digoxin can be increased when it is combined with Tiaprofenic acid.
TiboloneDigoxin may decrease the cardiotoxic activities of Tibolone.
TicagrelorThe serum concentration of Digoxin can be increased when it is combined with Ticagrelor.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Digoxin.
TiclopidineThe metabolism of Digoxin can be decreased when combined with Ticlopidine.
TimololTimolol may increase the bradycardic activities of Digoxin.
TimololThe serum concentration of Timolol can be decreased when it is combined with Digoxin.
TioguanineDigoxin may decrease the cardiotoxic activities of Tioguanine.
TipifarnibDigoxin may decrease the cardiotoxic activities of Tipifarnib.
TipranavirThe serum concentration of Digoxin can be increased when it is combined with Tipranavir.
TirapazamineDigoxin may decrease the cardiotoxic activities of Tirapazamine.
TizanidineDigoxin may increase the bradycardic activities of Tizanidine.
TobramycinThe serum concentration of Digoxin can be decreased when it is combined with Tobramycin.
TocilizumabThe serum concentration of Digoxin can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Digoxin.
Tolfenamic AcidThe serum concentration of Digoxin can be increased when it is combined with Tolfenamic Acid.
TolmetinThe serum concentration of Digoxin can be increased when it is combined with Tolmetin.
TolvaptanThe serum concentration of Digoxin can be increased when it is combined with Tolvaptan.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Digoxin.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Digoxin.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin.
ToremifeneDigoxin may decrease the cardiotoxic activities of Toremifene.
TositumomabDigoxin may decrease the cardiotoxic activities of Tositumomab.
TrabectedinDigoxin may decrease the cardiotoxic activities of Trabectedin.
TrametinibDigoxin may decrease the cardiotoxic activities of Trametinib.
TrandolaprilThe serum concentration of Digoxin can be increased when it is combined with Trandolapril.
TranilastThe serum concentration of Digoxin can be increased when it is combined with Tranilast.
TrastuzumabDigoxin may decrease the cardiotoxic activities of Trastuzumab.
Trastuzumab emtansineDigoxin may decrease the cardiotoxic activities of Trastuzumab emtansine.
TrazodoneThe serum concentration of Digoxin can be decreased when it is combined with Trazodone.
TretinoinDigoxin may decrease the cardiotoxic activities of Tretinoin.
TriamtereneThe therapeutic efficacy of Digoxin can be decreased when used in combination with Triamterene.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin.
TrifluoperazineThe serum concentration of Digoxin can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Digoxin can be increased when it is combined with Triflupromazine.
TrifluridineDigoxin may decrease the cardiotoxic activities of Trifluridine.
TrilostaneDigoxin may decrease the cardiotoxic activities of Trilostane.
TrimethoprimThe serum concentration of Digoxin can be increased when it is combined with Trimethoprim.
TrimetrexateDigoxin may decrease the cardiotoxic activities of Trimetrexate.
TrimipramineThe serum concentration of Digoxin can be increased when it is combined with Trimipramine.
TriptorelinDigoxin may decrease the cardiotoxic activities of Triptorelin.
Trisalicylate-cholineThe serum concentration of Digoxin can be increased when it is combined with Trisalicylate-choline.
TroleandomycinThe serum concentration of Digoxin can be increased when it is combined with Troleandomycin.
TrovafloxacinDigoxin may decrease the cardiotoxic activities of Trovafloxacin.
TroxacitabineDigoxin may decrease the cardiotoxic activities of Troxacitabine.
TTNPBDigoxin may decrease the cardiotoxic activities of TTNPB.
TubercidinDigoxin may decrease the cardiotoxic activities of Tubercidin.
UbenimexThe serum concentration of Digoxin can be increased when it is combined with Ubenimex.
UbenimexDigoxin may decrease the cardiotoxic activities of Ubenimex.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Digoxin.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Digoxin.
Uracil mustardDigoxin may decrease the cardiotoxic activities of Uracil mustard.
ValdecoxibThe serum concentration of Digoxin can be increased when it is combined with Valdecoxib.
ValrubicinDigoxin may decrease the cardiotoxic activities of Valrubicin.
VandetanibThe serum concentration of Digoxin can be increased when it is combined with Vandetanib.
VandetanibDigoxin may decrease the cardiotoxic activities of Vandetanib.
VapreotideDigoxin may decrease the cardiotoxic activities of Vapreotide.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Digoxin.
VeliparibDigoxin may decrease the cardiotoxic activities of Veliparib.
VemurafenibThe serum concentration of Digoxin can be increased when it is combined with Vemurafenib.
VemurafenibDigoxin may decrease the cardiotoxic activities of Vemurafenib.
VenlafaxineThe metabolism of Digoxin can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Digoxin.
VerapamilThe metabolism of Digoxin can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Digoxin.
VerteporfinDigoxin may decrease the cardiotoxic activities of Verteporfin.
VilazodoneThe serum concentration of Digoxin can be increased when it is combined with Vilazodone.
VildagliptinThe serum concentration of Digoxin can be increased when it is combined with Vildagliptin.
VinblastineDigoxin may decrease the cardiotoxic activities of Vinblastine.
VinblastineThe serum concentration of Digoxin can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Digoxin.
VincristineThe serum concentration of Digoxin can be decreased when it is combined with Vincristine.
VindesineDigoxin may decrease the cardiotoxic activities of Vindesine.
VinorelbineDigoxin may decrease the cardiotoxic activities of Vinorelbine.
VinorelbineThe serum concentration of Digoxin can be increased when it is combined with Vinorelbine.
VismodegibDigoxin may decrease the cardiotoxic activities of Vismodegib.
Vitamin ADigoxin may decrease the cardiotoxic activities of Vitamin A.
VoriconazoleThe metabolism of Digoxin can be decreased when combined with Voriconazole.
VorinostatDigoxin may decrease the cardiotoxic activities of Vorinostat.
XimelagatranThe serum concentration of Digoxin can be increased when it is combined with Ximelagatran.
ZaltoprofenThe serum concentration of Digoxin can be increased when it is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Digoxin.
ZileutonThe serum concentration of Digoxin can be increased when it is combined with Zileuton.
ZimelidineThe serum concentration of Digoxin can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Digoxin can be decreased when combined with Ziprasidone.
ZomepiracThe serum concentration of Digoxin can be increased when it is combined with Zomepirac.
Food Interactions
  • Avoid avocado.
  • Avoid bran and high fiber foods within 2 hours of taking this medication.
  • Avoid excess salt/sodium unless otherwise instructed by your physician.
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Avoid salt substitutes containing potassium.
  • Limit garlic, ginger, gingko, and horse chestnut.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Ravikumar A, Arun P, Devi KV, Augustine J, Kurup PA: Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders. Indian J Exp Biol. 2000 May;38(5):438-46. [PubMed:11272406 ]
  2. Chen JJ, Wang PS, Chien EJ, Wang SW: Direct inhibitory effect of digitalis on progesterone release from rat granulosa cells. Br J Pharmacol. 2001 Apr;132(8):1761-8. [PubMed:11309248 ]
  3. Ke YS, Liu ZF, Yang H, Yang T, Huang JS, Rui SB, Cheng GH, Wang YX: Effect of anti-digoxin antiserum on endoxin and membrane ATPase activity in hypoxia-reoxygenation induced myocardial injury. Acta Pharmacol Sin. 2000 Apr;21(4):345-7. [PubMed:11324464 ]
  4. Kumar AR, Kurup PA: A hypothalamic digoxin mediated model for conscious and subliminal perception. J Neural Transm (Vienna). 2001;108(7):855-68. [PubMed:11515751 ]
  5. Aizman O, Uhlen P, Lal M, Brismar H, Aperia A: Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13420-4. Epub 2001 Oct 30. [PubMed:11687608 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:
CYP11A1
Uniprot ID:
P05108
Molecular Weight:
60101.87 Da
References
  1. Chen JJ, Wang PS, Chien EJ, Wang SW: Direct inhibitory effect of digitalis on progesterone release from rat granulosa cells. Br J Pharmacol. 2001 Apr;132(8):1761-8. [PubMed:11309248 ]
  2. Wang SW, Pu HF, Kan SF, Tseng CI, Lo MJ, Wang PS: Inhibitory effects of digoxin and digitoxin on corticosterone production in rat zona fasciculata-reticularis cells. Br J Pharmacol. 2004 Aug;142(7):1123-30. Epub 2004 Jul 12. [PubMed:15249423 ]
  3. Lin H, Wang SW, Tsai SC, Chen JJ, Chiao YC, Lu CC, Huang WJ, Wang GJ, Chen CF, Wang PS: Inhibitory effect of digoxin on testosterone secretion through mechanisms involving decreases of cyclic AMP production and cytochrome P450scc activity in rat testicular interstitial cells. Br J Pharmacol. 1998 Dec;125(8):1635-40. [PubMed:9886754 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Tsujimoto M, Ohnishi N, Yokoyama T: Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun. 2002 Mar 22;292(1):190-4. [PubMed:11890691 ]
  2. Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T: Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun. 2003 Jun 20;306(1):116-20. [PubMed:12788075 ]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  4. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9. [PubMed:10746169 ]
  5. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899 ]
  6. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  7. Neuhoff S, Ungell AL, Zamora I, Artursson P: pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003 Aug;20(8):1141-8. [PubMed:12948010 ]
  8. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  9. Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2004 Jan 15;67(2):269-76. [PubMed:14698039 ]
  10. Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P: Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci. 2004 Jan;21(1):69-75. [PubMed:14706813 ]
  11. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992 Nov;263(2):840-5. [PubMed:1359120 ]
  12. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation. 1999 Feb 2;99(4):552-7. [PubMed:9927403 ]
  13. Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ: Grapefruit juice activates P-glycoprotein-mediated drug transport. Pharm Res. 1999 Apr;16(4):478-85. [PubMed:10227700 ]
  14. Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26. [PubMed:15180340 ]
  15. Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8. [PubMed:15032316 ]
  16. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783 ]
  17. Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. doi: 10.1016/j.phrs.2009.07.002. Epub 2009 Jul 21. [PubMed:19631272 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Organic anion transporter, capable of transporting pharmacological substances such as digoxin, ouabain, thyroxine, methotrexate and cAMP. May participate in the regulation of membrane transport of ouabain. Involved in the uptake of the dipeptidyl peptidase-4 inhibitor sitagliptin and hence may play a role in its transport into and out of renal proximal tubule cells. May be involved in the first...
Gene Name:
SLCO4C1
Uniprot ID:
Q6ZQN7
Molecular Weight:
78947.525 Da
References
  1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H: Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem. 1999 May 7;274(19):13675-80. [PubMed:10224140 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T: Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate. Biochem Biophys Res Commun. 2000 Sep 7;275(3):831-8. [PubMed:10973807 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35. [PubMed:10617675 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Hagenbuch B, Adler ID, Schmid TE: Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20. [PubMed:10600646 ]
  2. Noe B, Hagenbuch B, Stieger B, Meier PJ: Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10346-50. [PubMed:9294213 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efficiently transports the major species of bile acids.
Gene Name:
SLC51A
Uniprot ID:
Q86UW1
Molecular Weight:
37734.575 Da
References
  1. Seward DJ, Koh AS, Boyer JL, Ballatori N: Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. Epub 2003 Apr 28. [PubMed:12719432 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Essential component of the Ost-alpha/Ost-beta complex, a heterodimer that acts as the intestinal basolateral transporter responsible for bile acid export from enterocytes into portal blood. Efficiently transports the major species of bile acids. Modulates SLC51A glycosylation, membrane trafficking and stability activities.
Gene Name:
SLC51B
Uniprot ID:
Q86UW2
Molecular Weight:
14346.195 Da
References
  1. Seward DJ, Koh AS, Boyer JL, Ballatori N: Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. Epub 2003 Apr 28. [PubMed:12719432 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as the thyroid hormones T3 (triiodo-L-thyronine), T4 (thyroxine) and rT3, and of estrone-3-sulfate and taurocholate.
Gene Name:
SLCO4A1
Uniprot ID:
Q96BD0
Molecular Weight:
77192.505 Da
References
  1. Mikkaichi T, Suzuki T, Onogawa T, Tanemoto M, Mizutamari H, Okada M, Chaki T, Masuda S, Tokui T, Eto N, Abe M, Satoh F, Unno M, Hishinuma T, Inui K, Ito S, Goto J, Abe T: Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. Epub 2004 Mar 1. [PubMed:14993604 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. [PubMed:11159893 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Thyroid hormone transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent high affinity transport of organic anions such as the thyroid hormones thyroxine (T4) and rT3. Other potential substrates, such as triiodothyronine (T3), 17-beta-glucuronosyl estradiol, estrone-3-sulfate and sulfobromophthalein (BSP) are transported with much lower efficiency. May play a signifiant role in regulating T4 flux into and out of the brain (By similarity).
Gene Name:
SLCO1C1
Uniprot ID:
Q9NYB5
Molecular Weight:
78695.625 Da
References
  1. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ: Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. [PubMed:12351693 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. van Montfoort JE, Schmid TE, Adler ID, Meier PJ, Hagenbuch B: Functional characterization of the mouse organic-anion-transporting polypeptide 2. Biochim Biophys Acta. 2002 Aug 19;1564(1):183-8. [PubMed:12101011 ]
  2. Dagenais C, Ducharme J, Pollack GM: Uptake and efflux of the peptidic delta-opioid receptor agonist. Neurosci Lett. 2001 Apr 6;301(3):155-8. [PubMed:11257421 ]
  3. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y: Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. J Pharmacol Exp Ther. 2001 Jul;298(1):316-22. [PubMed:11408557 ]
  4. Hagenbuch N, Reichel C, Stieger B, Cattori V, Fattinger KE, Landmann L, Meier PJ, Kullak-Ublick GA: Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver. J Hepatol. 2001 Jun;34(6):881-7. [PubMed:11451172 ]
  5. Gao B, Wenzel A, Grimm C, Vavricka SR, Benke D, Meier PJ, Reme CE: Localization of organic anion transport protein 2 in the apical region of rat retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2002 Feb;43(2):510-4. [PubMed:11818398 ]
  6. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y: Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm Res. 2002 Feb;19(2):147-53. [PubMed:11883641 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23